Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT02903381Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: 2 Year Progression Free Percent. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02903381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903381.